Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA expression profile of dermal MSCs derived from psoriasis patients and normal control

ABSTRACT: Several studies have suggested that MSCs have pleiotropic immuno-modulatory effects, including inhibition of T cell proliferation, suppression of NK cells proliferation, modulation of cytokine production, and inhibition of dendritic cell (DC) maturation etc. But the exactly mechanism are still largely unclear. We proposed to investigate the microRNA expression profile of psoriatic MSCs.

ORGANISM(S): Merkel cell polyomavirus Mus musculus Human gammaherpesvirus 8 JC polyomavirus Rattus norvegicus Betapolyomavirus macacae Murid gammaherpesvirus 4 Homo sapiens Human immunodeficiency virus 1 Human betaherpesvirus 5 Human alphaherpesvirus 2 Betapolyomavirus hominis Human alphaherpesvirus 1 human gammaherpesvirus 4 Mus musculus cytomegalovirus 2 Murid betaherpesvirus 1

PROVIDER: GSE42633 | GEO | 2012/11/30

SECONDARY ACCESSION(S): PRJNA182384

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

methylation profile of dermal MSCs derived from psoriasis patients and normal control

Project description:Several studies have suggested that MSCs have pleiotropic immuno-modulatory effects, including inhibition of T cell proliferation, suppression of NK cells proliferation, modulation of cytokine production, and inhibition of dendritic cell (DC) maturation etc. But the exactly mechanism are still largely unclear.We have found that the gene expression profile of psoriatic dermal MSCs was distinct different from normal MSCs. We proposed to investigate the DNA methylation profile of psoriatic MSCs. 6 patients and 6 normal control were inrolled in the study, the DNA methylation profile of dermal MSCs were studied using the microarry.

2012-11-30 | E-GEOD-42634 | biostudies-arrayexpress

methylation profile of dermal MSCs derived from psoriasis patients and normal control

2012-11-30 | GSE42634 | GEO

mRNA expression profile of dermal MSCs derived from psoriasis patients and normal control

2012-11-30 | GSE42632 | GEO

microRNA expression profile of dermal MSCs derived from psoriasis patients and normal control

Project description:Several studies have suggested that MSCs have pleiotropic immuno-modulatory effects, including inhibition of T cell proliferation, suppression of NK cells proliferation, modulation of cytokine production, and inhibition of dendritic cell (DC) maturation etc. But the exactly mechanism are still largely unclear. We proposed to investigate the microRNA expression profile of psoriatic MSCs. 6 patients and 6 normal control were inrolled in the study, the microRNA expression profile of dermal MSCs were studied using the microarry.

2012-11-30 | E-GEOD-42633 | biostudies-arrayexpress

mRNA expression profile of dermal MSCs derived from psoriasis patients and normal control

Project description:Several studies have suggested that MSCs have pleiotropic immuno-modulatory effects, including inhibition of T cell proliferation, suppression of NK cells proliferation, modulation of cytokine production, and inhibition of dendritic cell (DC) maturation etc. But the exactly mechanism are still largely unclear. We proposed to investigate the mRNA expression profile of psoriatic MSCs. 6 patients and 6 normal control were inrolled in the study, the mRNA expression profile of dermal MSCs were studied using the microarry.

2012-11-30 | E-GEOD-42632 | biostudies-arrayexpress

Tsirvouli2023 - PsoriaSys model: a multiscale psoriasis model

Project description:The PsoriaSys model represent molecular and cellular interactions in the psoriatic microenvironment. The model is able to simulate the dynamics of keratinocyte proliferation in response to psoriatic triggers and perturbations. Dynamic simulations coupled with network graph metrics were used to identify target pairs with high influence on the system's behavior. Two target pairs, namely the combinatorial inhibition of neutrophil activation with PGE2 production or STAT3 activation, were predicted to reduce keratinocyte hyperproliferation at similar levels as IL-17 inhibition, which is the current standard treatment for moderate-to-severe cases.

2024-02-06 | MODEL2308300001 | BioModels

Transcriptional remodeling of human dermal blood vascular and lymphatic endothelial cells in psoriasis

Project description:Single-cell transcriptomic profiling of CD45-CD31+ endothelial cells derived from healthy and psoriatic human skin using the 10x Genomics platform.

2022-05-26 | E-MTAB-11218 | biostudies-arrayexpress

Hsa-miR-31-5p controls a metabolic switch in psoriatic keratinocytes that identifies therapeutic intervention

Project description:Next to genetic alterations, it is being recognized that the cellular environment also acts as a major determinant in onset and progression of disease. In cases where different cell types contribute to the final disease outcome, this imposes environmental challenges as different cell types likely differ in their extracellular dependencies. A number of skin diseases, including psoriasis is characterized by a combination of keratinocyte hyperproliferation and immune cell activation. Activation of immune cells involves increased glucose consumption thereby intrinsicly limiting glucose availability for other cell types. Thus, these type of skin diseases require metabolic adaptations that enable coexistence between hyperproliferative keratinocytes and activated immune cells in a nutrient-limited environment. Hsa-microRNA-31-5p (miR-31) is highly expressed in keratinocytes within the psoriatic skin. Here we show that miR-31 expression in keratinocytes is induced by limited glucose availability and enables increased survival of keratinocytes under limiting glucose conditions, by increasing glutamine metabolism. In addition, miR-31 induced glutamine metabolism results in secretion of specific metabolites (aspartate and glutamate) but also secretion of immuno-modulatory factors. We show that this miR-31-induced secretory phenotype is sufficient to induce Th17 cell differentiation, a hallmark of psoriasis. Inhibition of glutaminase (GLS) using CB-839 impedes miR31-induced metabolic rewiring and secretion of immuno-modulatory factors. Concordantly, pharmacological targeting of GLS alleviated psoriasis pathology in a mouse model of psoriasis. Together our data illustrate an emerging concept of metabolic interaction across cell compartments that characterizes disease development, which can be employed to design effective treatment options for disease, as shown here for psoriasis.

2023-02-06 | PXD029030 | Pride

RNA sequence of ISL1-MSCs and Ctrl-MSCs

Project description:RNA sequence of ISL1-MSCs and Ctrl-MSCs

| PRJNA421939 | ENA

Transcriptional regulatory networks of psoriasis

Project description:Psoriasis is a common inflammatory skin disease with complex etiology and chronic progression. To provide novel insights into the molecular mechanisms of regulation of the disease we performed RNA sequencing (RNA-Seq) analysis of fourteen pairs of skin samples collected from psoriatic patients with consequent pathway analysis and identification of the main transcriptional regulators of psoriasis-associated pathways. In order to identify the most important regulators of the disease, we combined the results obtained with MetaCore Interactome enrichment tool and cisExpress algorithm and compared them to regulatory psoriasis response elements found in literature. Comparative approach allowed us to identify 42 core transcriptional regulators of the disease associated with inflammation (NFkB, IRF9, JUN, FOS, SRF), activity of T-cells in the psoriatic lesions (STAT6, FOXP3, NFATC2, GATA3, TCF7, RUNX1, etc.), hyper-proliferation and migration of keratinocytes (JUN, FOS, NFIB, TFAP2A, TFAP2C), and with lipid metabolism (TFAP2, RARA, VDR). We also identified 66 transcription factors not previously associated with psoriasis. Using MetaCore pathway maps we illustrated and described the molecular basis of psoriatic skin lesions.

2017-09-14 | GSE78023 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data